JCU - January 2022 - 45

Green-Lott et al.
45
as seen in our patient, up to 15 years postdiagnosis have
been reported.7,10 Preliminary data in the use of singleagent
immunotherapy targeting programmed cell death
ligand-1 (PD-L1), expressed highly in malignant pleural
mesothelioma, suggest a promising alternative. In one trial
of 25 patients treated with pembrolizumab, 5 (20%) demonstrated
positive response and 13 (52%) remained with
stable disease.11 Another trial published in 2019 observed
both durable antitumor activity and disease control with
avelumab (median overall survival of 10 months) in
patients with advanced unresectable mesothelioma.12
Conclusion
Our case of WDPM further supports the trend that WDPM
has a propensity for a benign clinical course and management
with a testis-sparing approach is feasible, although
long-term oncologic outcomes are unknown. In addition,
our case of MM demonstrates that even with negative surgical
margins, no evidence of metastasis at time of diagnosis
and adjuvant treatment with chemotherapy, long-term
surveillance is critical to identify late recurrences.
Conflicting Interests
The opinions and assertions expressed herein are those of the
authors and do not necessarily reflect the official policy or position
of the Department of Defense. This work was prepared by
military employees of the United States government as part of the
individuals' official duties and therefore is in the public domain
and does not possess copyright protection (public domain information
may be freely distributed and copied; however, as a courtesy
it is requested that the Naval Medical Center San Diego and
the authors be given appropriate acknowledgement).
Funding
This research received no specific grant from any funding agency
in the public, commercial, or not-for-profit sectors.
Ethical Approval
Our institution does not require ethical approval for reporting
individual cases or case series.
Informed Consent
Written informed consent was obtained from the patients for
their anonymized information to be published in this article.
Guarantor
PHK.
Contributorship
NR conceived the study. NR and AG researched the literature
and wrote the first draft. NR and AG researched the literature and
wrote the second draft. PHK and BML edited the third draft. All
authors reviewed and edited the manuscript and approved the
final version of the manuscript.
Acknowledgements
None.
ORCID iD
Ashley-Marie Y. Green-Lott
8725-1499
https://orcid.org/0000-0002References
1.
Cutts R, Connor MJ, Sun L, et al. Mesothelioma subtypes of
the tunica vaginalis: A rare case report and review of histological
criteria. J Surg Case Rep 2019; 2019: rjz040.
2. Recabal P, Rosenzweig B, Bazzi WM, et al. Malignant mesothelioma
of the tunica vaginalis testis: Outcomes following
surgical management beyond radical orchiectomy. Urology
2017; 107: 166-170.
3. Brimo F, Illei PB and Epstein JI. Mesothelioma of the tunica
vaginalis: A series of eight cases with uncertain malignant
potential. Mod Pathol 2010; 23: 1165-1172.
4. Mezei G, Chang ET, Mowat FS, et al. Epidemiology of
mesothelioma of the pericardium and tunica vaginalis testis.
Ann Epidemiol 2017; 27: 348-359.e311.
5. Mensi C, Pellegatta M, Sieno C, et al. Mesothelioma of
tunica vaginalis testis and asbestos exposure. BJU Int 2012;
110: 533-537.
6. Perez-Ordonez B and Srigley JR. Mesothelial lesions of the
paratesticular region. Semin Diagn Pathol 2000; 17: 294-
306.
7. Plas E, Riedl CR and Pflüger H. Malignant mesothelioma
of the tunica vaginalis testis: Review of the literature and
assessment of prognostic parameters. Cancer 1998; 83:
2437-2446.
8. Gupta NP and Kumar R. Malignant gonadal mesothelioma.
Curr Treat Options Oncol 2002; 3: 363-367.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III
study of pemetrexed in combination with cisplatin versus
cisplatin alone in patients with malignant pleural mesothelioma.
J Clin Oncol 2003; 21: 2636-2644.
10. Jones MA, Young RH and Scully RE. Malignant mesothelioma
of the tunica vaginalis. A clinicopathologic analysis
of 11 cases with review of the literature. Am J Surg Pathol
1995; 19: 815-825.
11. Alley EW, Lopez J, Santoro A, et al. Clinical safety and
activity of pembrolizumab in patients with malignant pleural
mesothelioma (KEYNOTE-028): Preliminary results
from a non-randomised, open-label, phase 1b trial. Lancet
Oncol 2017; 18: 623-630.
12. Hassan R, Thomas A, Nemunaitis JJ, et al. Efficacy and
safety of avelumab treatment in patients with advanced
unresectable mesothelioma: Phase 1b results from the
JAVELIN Solid Tumor Trial. JAMA Oncol 2019; 5: 351-
357.
https://www.orcid.org/0000-0002-8725-1499 https://www.orcid.org/0000-0002-8725-1499

JCU - January 2022

Table of Contents for the Digital Edition of JCU - January 2022

Contents
JCU - January 2022 - Cover1
JCU - January 2022 - Contents
JCU - January 2022 - 2
JCU - January 2022 - 3
JCU - January 2022 - 4
JCU - January 2022 - 5
JCU - January 2022 - 6
JCU - January 2022 - 7
JCU - January 2022 - 8
JCU - January 2022 - 9
JCU - January 2022 - 10
JCU - January 2022 - 11
JCU - January 2022 - 12
JCU - January 2022 - 13
JCU - January 2022 - 14
JCU - January 2022 - 15
JCU - January 2022 - 16
JCU - January 2022 - 17
JCU - January 2022 - 18
JCU - January 2022 - 19
JCU - January 2022 - 20
JCU - January 2022 - 21
JCU - January 2022 - 22
JCU - January 2022 - 23
JCU - January 2022 - 24
JCU - January 2022 - 25
JCU - January 2022 - 26
JCU - January 2022 - 27
JCU - January 2022 - 28
JCU - January 2022 - 29
JCU - January 2022 - 30
JCU - January 2022 - 31
JCU - January 2022 - 32
JCU - January 2022 - 33
JCU - January 2022 - 34
JCU - January 2022 - 35
JCU - January 2022 - 36
JCU - January 2022 - 37
JCU - January 2022 - 38
JCU - January 2022 - 39
JCU - January 2022 - 40
JCU - January 2022 - 41
JCU - January 2022 - 42
JCU - January 2022 - 43
JCU - January 2022 - 44
JCU - January 2022 - 45
JCU - January 2022 - 46
JCU - January 2022 - 47
JCU - January 2022 - 48
JCU - January 2022 - 49
JCU - January 2022 - 50
JCU - January 2022 - 51
JCU - January 2022 - 52
JCU - January 2022 - 53
JCU - January 2022 - 54
JCU - January 2022 - 55
JCU - January 2022 - 56
JCU - January 2022 - 57
JCU - January 2022 - 58
JCU - January 2022 - 59
JCU - January 2022 - 60
JCU - January 2022 - 61
JCU - January 2022 - 62
JCU - January 2022 - 63
JCU - January 2022 - 64
JCU - January 2022 - 65
JCU - January 2022 - 66
JCU - January 2022 - 67
JCU - January 2022 - 68
JCU - January 2022 - 69
JCU - January 2022 - 70
JCU - January 2022 - 71
JCU - January 2022 - 72
JCU - January 2022 - 73
JCU - January 2022 - 74
JCU - January 2022 - 75
JCU - January 2022 - 76
JCU - January 2022 - 77
JCU - January 2022 - 78
JCU - January 2022 - Cover3
JCU - January 2022 - Cover4
https://www.nxtbookmedia.com